Factors influencing the emergence of resistance to indinavir: Role of virologic, immunologic, and pharmacologic variables

Journal of Infectious Diseases

Volumn 178, Issue 2, 1998, Pages 360-367

  Drusano, G L ^a   Bilello, J A ^b   Stein, D S ^b   Nessly, M ^b   Meibohm, A ^b   Emini, E A ^b   Deutsch, P ^b   Condra, J ^b   Chodakewitz, J ^b   Holder, D J ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; RNA ANALYSIS; VIRUS LOAD; VIRUS RESISTANCE;

EID: 17344363832     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515631     Document Type: Article

References (17)

1. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
2. Welles SL, Jackson JB, Yen-Lieberman B, et al. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. J Infect Dis 1996;174:696-703.
3. Coombs RW, Welles SL, Hooper C, et al. Association of plasma human immunodeficiency virus type 1 (HIV-1) RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996;174:704-12.
4. Mayers, D, Saravolatz L, Winslow D, et al. Viral burden measurements in CPCRA 007 [abstract LB031]. In: Program and abstracts: XI International Conference on AIDS (Vancouver, Canada). Vancouver: XI International Conference on AIDS Society, 1996.
5. National Institutes of Allergy and Infectious Diseases, Division of AIDS. ACTG virology manual for HIV laboratories. 3rd ed. Bethesda, MD: National Institutes of Health, 1994; publication no. (NIH)94-3828.
6. Japour AJ, Fiscus SA, Arduino JM, et al. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol 1994;32:2291-4.
7. Condra JH, Schleif WA, Blay OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374;569-71.
8. Cox DR. Regression models and life tables. J R Stat Soc Ser B 1972;34:187-202.
9. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982;69:239-41.
10. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-26.
11. Harrell F. The PHGLM procedure. SAS Supplemental Library user's guide. 5th ed. Cary, NC: SAS Institute, 1986.
12. St Clair MH, Hartigan PM, Andrews JC, et al. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. J Acquir Immune Defic Syndr Hum Retrovirol 1993;6:891-7.
13. + cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-8.
14. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994;169:968-74.
15. Condra, JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996;70:8270-6.
16. Drusano GL, Stein DS. Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor indinavir. Antimicrob Agents Chemother 1998;42:358-61.
17. Drusano GL. Antiviral therapy of HIV and cytomegalovirus [abstract S-121]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997.